EBS - Emergent Biosolutions Inc
Close
8.31
-0.600 -7.220%
Share volume: 9,843,555
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$8.91
-0.60
-6.73%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-02 | 2022-11-09 | 2023-03-01 | 2023-05-10 | 2023-08-09 | 2023-12-11 | 2024-03-08 | 2024-05-02 | |
| Assets | |||||||||
| Total Assets | 2.735 B | 2.909 B | 3.167 B | 2.950 B | 2.179 B | 1.893 B | 1.823 B | 1.804 B | |
| Current Assets | 1.084 B | 1.119 B | 1.211 B | 1.221 B | 777.700 M | 720.800 M | 679.500 M | 682.400 M | |
| Inventories | 425.500 M | 546.300 M | 351.800 M | 367.900 M | 354.300 M | 354.100 M | 328.900 M | 333.400 M | |
| Other Current Assets | 125.400 M | 139.900 M | 57.900 M | 41.700 M | 44.700 M | 62.400 M | 47.900 M | 36.500 M | |
| Short Term Investments | 125.400 M | 139.900 M | 57.900 M | 41.700 M | 44.700 M | 62.400 M | 47.900 M | 36.500 M | |
| Total Receivables | 175.000 M | 191.300 M | 158.400 M | 155.900 M | 290.100 M | 216.500 M | 191.000 M | 233.500 M | |
| Current Cash | 358.100 M | 240.900 M | 642.600 M | 430.200 M | 88.600 M | 87.800 M | 111.700 M | 78.500 M | |
| Total Non-current Assets | 1.651 B | 1.790 B | 1.956 B | 1.729 B | 1.401 B | 1.172 B | 1.144 B | 1.121 B | |
| Property Plant Equipment | 798.400 M | 806.700 M | 817.600 M | 716.800 M | 395.500 M | 395.400 M | 382.800 M | 379.400 M | |
| Other Assets | 51.300 M | 35.700 M | 191.300 M | 184.600 M | 194.600 M | 194.100 M | 194.300 M | 191.400 M | |
| Intangible Assets | 576.600 M | 722.700 M | 728.800 M | 608.900 M | 592.800 M | 582.800 M | 566.600 M | 550.400 M | |
| Goodwill | 224.900 M | 224.900 M | 218.200 M | 218.200 M | 218.200 M | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.735 B | 2.909 B | 3.167 B | 2.950 B | 2.179 B | 1.893 B | 1.823 B | 1.804 B | |
| Total liabilities | 1.222 B | 1.459 B | 1.784 B | 1.747 B | 1.223 B | 1.196 B | 1.174 B | 1.140 B | |
| Total current liabilities | 276.700 M | 268.400 M | 1.230 B | 1.216 B | 693.200 M | 664.000 M | 651.300 M | 630.200 M | |
| Accounts Payable | 106.200 M | 103.800 M | 103.500 M | 124.200 M | 108.300 M | 112.700 M | 112.200 M | 100.200 M | |
| Other liabilities | 58.500 M | 44.900 M | 33.400 M | 24.100 M | 23.400 M | 31.300 M | 28.900 M | 28.000 M | |
| Current long term debt | 31.600 M | 21.200 M | 957.300 M | 950.700 M | 455.200 M | 413.600 M | 413.700 M | 459.200 M | |
| Long term debt | 793.600 M | 1.032 B | 448.500 M | 447.700 M | 448.000 M | 448.200 M | 446.500 M | 446.700 M | |
| Other liabilities | 58.500 M | 44.900 M | 33.400 M | 24.100 M | 23.400 M | 31.300 M | 28.900 M | 28.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.513 B | 1.449 B | 1.383 B | 1.203 B | 956.300 M | 697.200 M | 649.300 M | 663.900 M | |
| Common stock | 50.000 M | 49.900 M | 49.800 M | 50.200 M | 50.700 M | 51.800 M | 52.100 M | 52.200 M | |
| Retained earnings | 897.700 M | 822.000 M | 734.000 M | 551.000 M | 289.700 M | 27.700 M | -21.800 M | -12.800 M |